300639 Stock Overview
Engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Guangdong Hybribio Biotech Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.40 |
| 52 Week High | CN¥9.40 |
| 52 Week Low | CN¥4.32 |
| Beta | 0.47 |
| 1 Month Change | -2.14% |
| 3 Month Change | 26.48% |
| 1 Year Change | -31.18% |
| 3 Year Change | -47.90% |
| 5 Year Change | -23.48% |
| Change since IPO | 63.33% |
Recent News & Updates
Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
Oct 08
Is Guangdong Hybribio BiotechLtd (SZSE:300639) Using Debt In A Risky Way?
Sep 29Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) 77% Share Price Surge Not Quite Adding Up
Aug 19Recent updates
Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
Oct 08Is Guangdong Hybribio BiotechLtd (SZSE:300639) Using Debt In A Risky Way?
Sep 29Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) 77% Share Price Surge Not Quite Adding Up
Aug 19Guangdong Hybribio BiotechLtd (SZSE:300639) Is Reducing Its Dividend To CN¥0.065
May 22There May Be Some Bright Spots In Guangdong Hybribio BiotechLtd's (SZSE:300639) Earnings
May 03Shareholder Returns
| 300639 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -3.8% | -1.9% | -1.2% |
| 1Y | -31.2% | -16.2% | 11.8% |
Return vs Industry: 300639 underperformed the CN Biotechs industry which returned -16.2% over the past year.
Return vs Market: 300639 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 300639 volatility | |
|---|---|
| 300639 Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300639 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300639's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2,485 | Jianyu Wang | www.hybribio.cn |
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal.
Guangdong Hybribio Biotech Co.,Ltd. Fundamentals Summary
| 300639 fundamental statistics | |
|---|---|
| Market cap | CN¥4.07b |
| Earnings (TTM) | -CN¥293.55m |
| Revenue (TTM) | CN¥864.07m |
4.7x
P/S Ratio-13.9x
P/E RatioIs 300639 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300639 income statement (TTM) | |
|---|---|
| Revenue | CN¥864.07m |
| Cost of Revenue | CN¥397.77m |
| Gross Profit | CN¥466.30m |
| Other Expenses | CN¥759.85m |
| Earnings | -CN¥293.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 53.97% |
| Net Profit Margin | -33.97% |
| Debt/Equity Ratio | 1.6% |
How did 300639 perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield-12%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guangdong Hybribio Biotech Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hanqing Zhu | Guosen Securities Co., Ltd. |
| Jiaxi Xu | Industrial Securities Co. Ltd. |
| Jiaqi Zhu | Zhongtai Securities Co. Ltd. |